MX372711B - Metodos para la purificacion de arilsulfatasa a. - Google Patents

Metodos para la purificacion de arilsulfatasa a.

Info

Publication number
MX372711B
MX372711B MX2015008875A MX2015008875A MX372711B MX 372711 B MX372711 B MX 372711B MX 2015008875 A MX2015008875 A MX 2015008875A MX 2015008875 A MX2015008875 A MX 2015008875A MX 372711 B MX372711 B MX 372711B
Authority
MX
Mexico
Prior art keywords
asa
arylsulfatase
present
methods
purification
Prior art date
Application number
MX2015008875A
Other languages
English (en)
Spanish (es)
Other versions
MX2015008875A (es
Inventor
Bee Lin Cheang
Mei Huei Jang
Dave Nichols
Igor Quinones-Garcia
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2015008875A publication Critical patent/MX2015008875A/es
Publication of MX372711B publication Critical patent/MX372711B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12Purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001Arylsulfatase (3.1.6.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2015008875A 2013-01-09 2014-01-09 Metodos para la purificacion de arilsulfatasa a. MX372711B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Publications (2)

Publication Number Publication Date
MX2015008875A MX2015008875A (es) 2015-10-22
MX372711B true MX372711B (es) 2020-04-21

Family

ID=50002885

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008875A MX372711B (es) 2013-01-09 2014-01-09 Metodos para la purificacion de arilsulfatasa a.
MX2020003798A MX2020003798A (es) 2013-01-09 2015-07-08 Metodos para la purificacion de arilsulfatasa a.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003798A MX2020003798A (es) 2013-01-09 2015-07-08 Metodos para la purificacion de arilsulfatasa a.

Country Status (12)

Country Link
US (3) US11407984B2 (enExample)
EP (1) EP2943568B1 (enExample)
JP (5) JP6427502B2 (enExample)
CN (4) CN112126634A (enExample)
AU (3) AU2014205441B2 (enExample)
BR (1) BR112015015948B1 (enExample)
CA (1) CA2896979C (enExample)
EA (1) EA030551B1 (enExample)
ES (1) ES2768261T3 (enExample)
HK (1) HK1214622A1 (enExample)
MX (2) MX372711B (enExample)
WO (1) WO2014110246A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625511T3 (es) * 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Métodos para la purificación de arylsulfatasa A
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
WO2016106291A1 (en) * 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
WO2017031476A2 (en) * 2015-08-20 2017-02-23 Genentech, Inc. Purification of fkpa and uses thereof for producing recombinant polypeptides
JP6985282B2 (ja) * 2016-03-16 2021-12-22 フェニックス ティシュー リペア インコーポレイテッドPhoenix Tissue Repair, Inc. 7型コラーゲンの精製方法
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
CN111699249A (zh) * 2017-12-19 2020-09-22 夏尔人类遗传性治疗公司 纯化的芳基硫酸酯酶a及其组合物
JP2021512853A (ja) * 2018-02-02 2021-05-20 エンジーヴァント セラピューティックス ゲーエムベーハー ファーバー病を処置するための方法
IL277797B1 (en) * 2018-04-12 2024-11-01 Amgen Inc Methods for making stable protein compositions
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
IL293529A (en) * 2019-12-12 2022-08-01 Lilly Co Eli Methods for viral inactivation by environmentally compatible detergents
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) * 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ES2177240T3 (es) 1998-01-27 2002-12-01 Hemebiotech As Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas.
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
SK288128B6 (sk) 1998-06-09 2013-10-02 Csl Behring Ag Process for purifying immunoglobulin G (IgG), liquid immunoglobulin product and use thereof for the preparation of a medicament
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
EP1202744B1 (en) 1999-07-27 2006-01-04 Zymenex A/S PRODUCTION OF rhPBGD
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002040686A2 (en) 2000-11-15 2002-05-23 Genzyme Corporation Expression system for recombinant proteins
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
EP1463512B1 (en) 2002-01-11 2014-05-28 biOasis Technologies Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
EP1740204B1 (en) 2004-04-01 2018-03-14 Chiesi Farmaceutici S.p.A. Medicinal use of alpha-mannosidase
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
BRPI0709737A2 (pt) 2006-04-04 2011-07-26 Zymenex As processo para concentraÇço de um polipeptÍdeo
CA2739352C (en) * 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
CA2803003C (en) * 2010-06-25 2022-11-22 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of arylsulfatase a
JP6045491B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 治療薬のcns送達
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法

Also Published As

Publication number Publication date
CN112126634A (zh) 2020-12-25
BR112015015948A2 (enExample) 2017-08-15
MX2015008875A (es) 2015-10-22
JP2024001160A (ja) 2024-01-09
US20150353904A1 (en) 2015-12-10
EA201590826A1 (ru) 2015-11-30
US20240392268A1 (en) 2024-11-28
JP6427502B2 (ja) 2018-11-21
MX2020003798A (es) 2020-08-03
JP7407161B2 (ja) 2023-12-28
US11884945B2 (en) 2024-01-30
AU2020201079A1 (en) 2020-03-05
AU2022221475B2 (en) 2025-05-22
HK1216429A1 (en) 2016-11-11
EP2943568A1 (en) 2015-11-18
JP2016504040A (ja) 2016-02-12
HK1214622A1 (zh) 2016-07-29
BR112015015948B1 (pt) 2022-05-17
CN104903442A (zh) 2015-09-09
US11407984B2 (en) 2022-08-09
JP7663649B2 (ja) 2025-04-16
AU2020201079B2 (en) 2022-05-26
AU2022221475A1 (en) 2022-09-22
AU2014205441A1 (en) 2015-06-25
JP2018171067A (ja) 2018-11-08
ES2768261T3 (es) 2020-06-22
AU2014205441B2 (en) 2019-12-12
JP2022023225A (ja) 2022-02-07
WO2014110246A1 (en) 2014-07-17
JP2020015750A (ja) 2020-01-30
CA2896979A1 (en) 2014-07-17
US20230235303A1 (en) 2023-07-27
CA2896979C (en) 2023-05-02
CN120665836A (zh) 2025-09-19
EA030551B1 (ru) 2018-08-31
EP2943568B1 (en) 2019-11-20
US12319940B2 (en) 2025-06-03
CN119979504A (zh) 2025-05-13

Similar Documents

Publication Publication Date Title
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
CA3254669A1 (en) Targeted integration of nucleic acids
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
HK1206755A1 (en) Low acidic species compositions and methods for producing and using the same
BR112018003127A2 (pt) purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
EA201391157A1 (ru) Антагонисты pcsk9
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
MX391716B (es) Promotor de catalasa modificado bidireccional de bacilo.
MX378585B (es) Sistema de expresion bacterial bicistronico
EA202091349A1 (ru) Способы культивирования клеток
EA201890710A1 (ru) Способ очистки гидролизата биомассы
EA201990593A1 (ru) Непрерывный способ для снижения гетерогенности терапевтического белка
CL2019003248A1 (es) Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
MX383505B (es) Eliminación de la cistina mediada por enzimas humanas.
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
UY34915A (es) Purificación de inhibidor de proteasa alfa1 derivado de cultivo celular
EA201790362A1 (ru) Солюбилизированный фермент и его применения
MX2021016092A (es) Metodos de purificacion de proteinas.
MX2022002774A (es) Método de captura y purificación de productos biológicos.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED